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Peptide synthesis at 60 °C
Fungicidal action
Membrane permeabilizationThis study expands the knowledge on chemical synthesis and properties of Hb40-61a as well as provides results
of the ﬁrst steps given towards knowing how it kills Candida cells. For the ﬁrst time, this peptide, its all-D ana-
logue (D-Hb40-61a) and its ﬂuorescently labeled analogue (FAM-Hb40-61a) were successfully assembled on
resin at 60 °C using conventional heating in all steps. Puriﬁed and characterized, these peptides exhibited very
low toxicity on human erythrocytes. Hb40-61a and D-Hb40-61a were equally active against Candida strains,
ruling out sterically speciﬁc interactions on their working mechanism. Cell permeabilization assays conﬁrmed
progressive damage of the yeast plasma membrane with increasing concentrations of Hb40-61a. While experi-
ment using theﬂuorescent probeDiBAC4(5) revealed that this synthetic hemocidin alters the yeast plasmamem-
brane potential, test employing DPH indicated that Hb40-61amight affect its dynamics. Exposure of the yeast
cells to FAM-Hb40-61a showed that the peptide accumulates in the cell membrane at the ½ MIC, but stains
about 97% of the cells at the MIC. Such effect is salt-dependent and partially energy-dependent. These new ﬁnd-
ings indicate that the central target of Hb40-61a in Candida cells is the plasmamembrane and that this synthetic
hemocidin should be considered as a potential candidacidal for topic uses.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Invasive candidiasis has become a worldwide concern as studies
from the last two decades have shown that Candida species are the
fourth most common cause of nosocomial bloodstream infection [1,2].
In fact, its mortality rate is now about 50% [3–5] and there is a global
shift in epidemiology towards non-albicans Candida species [6]. As to
candidemia, this is themajor problem in tertiary-care hospitals because
it causes morbidity andmortality in patients, especially in the immuno-
compromised ones [7]. Sadly, in Brazil, candidemia rates are 2–8 times
higher than those documented in the USA and Europe [8,9].
The commercial antifungals are polyenes (amphotericin B and nys-
tatin), azoles (ﬂuconazole, itraconazole and ketoconazole), ﬂucytosine
and echinocandins (caspofungin, micafungin and anidulafungin).
These compounds are no longer fully protecting people from fungal
infections due to their high toxicity (mainly polyenes) and possibilityre described as a communication
ss, G.; Constantinou-Kokotou, V.;
Peptide Society, Athens, Greece.to cause fungal resistance (mainly polyenes, azoles or echinocandins)
[10–14]. In addition, their indiscriminate use has been the main reason
of the current and growing number of organisms tolerant to them in
therapeutic doses, a situation that represents a serious risk mainly to
immunocompromised people [7].
Antimicrobial peptides (AMPs) are promising pharmacological com-
pounds and rich sources of knowledge owing to their potential as inhib-
itors of the growth or killers of a variety of microorganisms as well as
their antitumor and immunomodulator activities. The AMPs with anti-
fungal and fungicidal activities can be more speciﬁc, but share the
following properties with the other AMPs: they act quickly [15], they
are able to kill strains resistant to the commercial antibiotics and they
do not easily induce microorganism resistance [16]. Most of these
molecules have a short chain peptide (12 to 50 amino acids), net posi-
tive charge (+2 to +9) and amphipathic structure [17] containing
about 50% of hydrophobic residues [18]; they can acquire α-helix,
β-sheet, extended or loop structures [19]. All these features are respon-
sible for the initial stages of their mechanisms of action which are
(i) the electrostatic attraction to negatively charged phospholipids
and (ii) hydrophobicity-assisted insertion and disturbance of themem-
brane [20].
The expression hemocidin (hemoglobin microbicidal peptides) was
ﬁrst deﬁned by Mak and colleagues as a way of describing AMPs that
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myoglobin and cytochrome c) [21–23]. In 1999, we reported the
ﬁrst hemocidinwith antimicrobial activity generated in the gut contents
of the cattle tick Boophilus microplus by bovineα-hemoglobin proteoly-
sis: fragments 33–61, named Hb33-61, whose amino acid sequence is
F33LSFPTTKTYFPHFDLSHGSAQVKGHGAK61 [24]. Subsequently, other
hemocidins were described to be produced in vitro (for instance,
resulting from heme-binding protein digestion in the presence of
cyanogen bromide or from bovine hemoglobin proteolysis catalyzed
bypepsin) or in vivo (found in gut contents of the rabbit tickOrnithodorus
moubata or in human placental blood or, again, in the gut contents of the
cattle tick B. microplus) [21,25–40].
Recognizing that C-terminal amidation increases peptide resistance
to proteolysis and may potentiate its antimicrobial activity [24], in
2005 we reported the synthesis and study of the amidated analogue of
Hb33-61 F33LSFPTTKTYFPHFDLSHGSAQVKGHGAK-NH2 (Hb33-61a).
The puriﬁed synthetic hemocidin was four-fold more potent than
Hb33-61 in inhibiting the growth of Candida albicans MDM8 cells and,
when in 200 μM sodium dodecyl sulfate (SDS) micelles, it folded very
close to the structure acquired by fragments 33–61 while as part of
the native bovine hemoglobin α-chain [41]. Having observed that
Hb33-61 and Hb33-61a also presented low hemolysis and knowing
that reduction of molecular size is prized in pharmaceutical develop-
ment [42], we then examined the structure–activity relationship of
Hb33-61a using N- and C-terminally truncated analogues and proposed
that Hb40-61a (K40TYFPHFDLSHGSAQVKGHGAK61-NH2) could be its
minimal active portion. In fact, Hb33-61a and Hb40-61a presented
the same MIC (3.12–6.25 μM), causing the death of C. albicans MDM8,
as it was shown to contain the main structural elements found in
Hb33-61a: a β-turn in N-terminus (portion Lys40-Phe43) and a β-turn
(portion Ser49-Ser52) followed by an α-helix (portion Ala53-Lys61) in
the C-terminus, which led us to hypothesize that these two structured
regions, by ﬂuctuating independently in the lipid environment, could
act in a coordinated fashion to permeabilize the yeast plasma mem-
brane [43]. The mean hydrophobicity result for Hb40-61a, calculated
according to Kyte and Doolitle (http://www.bbcm.units.it/~tossi/
HydroCalc/HydroMCalc.html) was−1.1 [43], conﬁrming its, although
not perfect, amphipathic nature.
In those studies [24,40,42,43], Hb33-61, Hb33-61a and their truncat-
ed analogues, including Hb40-61a, were synthesized by stepwise solid-
phase syntheses (SPPS) using Boc chemistry (use of dichloromethane
and HF) and traditional protocols (room temperature in all synthetic
steps). The crude materials obtained were quite heterogeneous and
contained low amounts of the desired peptides, thus the ﬁnal yields
were very low, a limitation to be defeated.
In an attempt to expand the knowledge on chemical synthesis and
properties of Hb40-61a as well as to give the ﬁrst steps towards under-
standinghow this synthetic hemocidin kills Candida cells, we performed
the present study that comprises: (i) the ﬁrst solid-phase syntheses at
60 °C using conventional heating in all steps of Hb40-61a, D-Hb40-61a
(its all-D analogue) and FAM-Hb40-61a (its ﬂuorescently labeled
version); (ii) a comparative evaluation of the anticandidal and hemolytic
activities of these peptides; and (iii) experiments designed to examine
its properties and investigate at a general level how Hb40-61a kills
Candida cells.
2. Materials and methods
2.1. Peptide synthesis, puriﬁcation and chemical characterization
The peptides were manually synthesized using the Fmoc-chemistry
and protocols developed in our laboratories for stepwise solid-phase
synthesis (SPPS) at 60 °C in all steps using conventional heating
[44–46]. Peptide assembly started from RINK-amide or CLEAR amide
resin. Fmoc removal was done in 20% piperidine/DMF for 7 min (twice,
when needed). Fmoc-amino acids (2.5-fold excess) were coupled (andrecoupled, when needed) for 30 min in the presence of DIC/HOBt (1:1,
equimolar to the Fmoc-amino acid) or TBTU (equimolar to the Fmoc-
amino acid)/DIPEA (7.5-fold excess) in 20% DMSO/NMP or DMF as sol-
vent systems, respectively. Alternate washings of the peptide resins
employed 20%DMSO/NMP (for reactions carried-out in this solventmix-
ture) or DMF (for reactions performed in this solvent), MeOH (for RINK
resin) or isopropanol (for CLEAR). The coupling of the 5(6)-carboxyﬂuo-
rescein (FAM) to the resulting fully protected peptide-resins was also
performed at 60 °C using 5 equiv. of FAM, 5 equiv. of benzotriazole-
1-yl-oxy-tris-(dimethylamino)-phosphonium
hexaﬂuorophosphate (BOP) and 5 equiv. of HOBt in 20% DMSO/NMP
for 2 h [46,47]. Ninhydrin test was used to monitor each
deprotection or coupling reaction.
Full deprotection and simultaneous cleavage of the peptide from
resin were carried out in the presence of TFA (95%), water (2.5%) and
TIS (2.5%). The free peptide was precipitated in diisopropyl ether and
extracted with 0.1% TFA/water or 60% ACN/0.1% TFA/water. The
resulting solution was lyophilized to give the solid crude material.
Peptide puriﬁcation by reversed-phase high-performance liquid
chromatography (RP-HPLC) was performed on a Waters system com-
posed by a Delta 600 Pump, a 2487 Dual Absorbance detector, a
3725i-119 Rheodyne injector and a 600 Controller (Millford/MA, USA)
and a Kipp & Zonen SE 124 register connected to a Grace-Vydac C18
column (10 μm, 300 Å, 2.2 × 25.0 cm; Albany/OR, USA), a ﬂow rate of
9 mL/min, and a detection wavelength of 220 nm. The puriﬁcations
required two steps [48]: (1) triethylammonium phosphate (TEAP)/
water at pH 2.25 as solvent A, 50% ACN/TEAP as solvent B; (2) 0.1%
TFA/water as solvent A, 60% ACN/A as solvent B. Elution was achieved
using appropriate linear gradients.
Peptide identity was conﬁrmed by liquid chromatography coupled
to electrospray ionization mass spectrometry (LC-MS). LC was per-
formed on a Shimadzu system (Kyoto, Japan) composed by a TGU-20A3
degasser, two LC-20AD pumps, a 8125 Rheodyne and a CTO20A column
oven connected to a C18 pre-column (4.6 mm, 12 nm, 5 × 2 mm)
Shimpack GVP-ODS and a C18 column (4.6 mm, 12 nm, 150 × 2 mm).
MS used ESI positive mode and an ion trap Bruker instrument
(AmaZonX, Bruker Daltonics, Fahrenheitstrasse, Germany).
Peptide content, required for exact determination of peptide con-
centration in biological assays, was given by amino acid analysis, which
was done on a Dionex BioLC® Chromatography system (Sunnyvale/CA,
USA) composed by an AS40 automatic sampler, a GS50 quaternary
pump, an LC25 column oven, a 2 × 250 mm PA10 AminoPac ion-
exchange column and an ED50 electrochemical detector. Therefore,
prior to the biological assays, each peptide preparation had the precise
peptide concentration determined.
2.2. Fungal strains, antifungal and fungicidal activity assays
C. albicans (ATCC 90028), Candida krusei (ATCC 6258) and Candida
parapsilosis (ATCC 22019). The strainswere cultured overnight in an in-
cubator shaker at 30 °C in Sabouraud Dextrose Broth (DB, Sparks/MD,
USA. The cells were diluted 1:100 in the same medium and incubated
for 4 h at 30 °C to enrich the population of exponentially growing cells
and reach the log-phase. The cells were centrifuged for 5 min at
8000 g and washed three times with PDB or LB medium.
The antimicrobial activity was evaluated by liquid growth-inhibition
assay as described by us [41,43]. Mellitin was used as control. The MIC
values for the peptides were expressed as the intervals of concentra-
tions [a]–[b], where [a] is the highest concentration tested at which
the microorganism was growing and [b] is the lowest concentration
that inhibits the visible microbial growth. Peptide concentrations were
in the range of 0.19–100 μM. Three independent experiments were
performed.
For the candidacidal assays, C. albicans ATCC 90028, C. krusei ATCC
6258 and C. parapsilosis ATCC 22019 cells were incubated for 48 h in
the presence of the peptides or water (control) under the conditions
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concentrations (0.19–100 μM) were plated on nutrient agar. Three
independent experiments were performed.
2.3. pH dependence of antifungal activity of Hb40-61a
The activity against C. albicans ATCC 90028 cells was evaluated as
described above. PDB medium was prepared using buffer 10 mM Tris-
HCl, pH 7.4 or 10 mM sodium acetate, pH 5.5 [49].
2.4. Activity against human erythrocytes
The hemolytic activity wasmeasured as described by us [43]. Brieﬂy,
fresh human blood was obtained from three healthy individuals and
collected in BD Vacutainer® spray-coated K2EDTA tubes (BD, Oakville,
ON, Canada). The erythrocytes were harvested from blood by centri-
fugation at 4 °C and 300 g for 5 min, and washed three times in
phosphate-buffered saline (PBS, 10 mM Na2PO4 containing 140 mM
NaCl and 2.7 mM KCl, pH 7.4 and 313 mOsm/kg of water) or in
phosphate-buffered isotonic (IGP; potassium phosphate 1 mM with
287 mM of glucose; pH 7.4, 314 mOsm/kg of water). Peptides from
0.19 to 100 μM were incubated in microtubes with a suspension of
1.1% erythrocytes in PBS or IGP. After 1 h at 37 °C, the tubeswere centri-
fuged at 300 g for 5 min at 5 °C. Aliquots (100 μL) of the supernatants
were transferred to 96-well plates and hemolysis was monitored at
405 nm using a microliter plate reader. Negative and positive controls
were prepared in PBS or IGP and in PBS or IGP supplemented with
0.1% SDS, respectively. Three independent experiments were per-
formed. The hemolysis percentages were calculated using the following
equation, where A405 nm (peptide) is the absorption of supernatant solu-
tion after treatment of cells with peptide, A405 nm (0.1% SDS) is the absorp-
tion of supernatant solution after treatment of cells with 0.1% SDS to
mimic full hemolysis and A405 nm (PBS or IGP) is the absorption of super-
natant solution from cells without any treatment [50].
%Hemolysis ¼ A405 nm peptideð Þ
A405 nm 0:1%SDSð Þ  A405 nm PBS or IGPð Þ
100
The therapeutic index (TI) was deﬁned as the ratio MHC/MIC. Mini-
mum hemolytic concentration (MHC) corresponds to the peptide con-
centration that causes 10% hemolysis.
2.5. Membrane permeability assay
Log-phased C. albicans ATCC 90028 cells (2 × 106 cells) were
harvested by centrifugation, washed three times, suspended in a PDB
mediumand treatedwith theKit Live/Dead Funga Light® Yeast Viability
Stain (Molecular Probes, Eugene/OR, USA) following themanufacturer's
instructions. This kit utilizes a mixture of the green ﬂuorescent nucleic
acid stain SYTO 9 with the red-ﬂuorescent nucleic acid stain propidium
iodide (PI). These stains differ not only for their spectral characteristics,
but also for their ability to penetrate bacteria cells. In fact, SYTO 9 stains
the DNA of all bacteria irrespective if they have themembrane intact or
damaged. In contrast, PI penetrates only cells with damaged mem-
branes. In addition, PI is able to quench the ﬂuorescence of SYTO 9. As
a result, when cells are stained with a mixture of these two ﬂuorescent
dyes, the oneswith intactmembranes appear greenwhereas thosewith
damaged membranes turn out to be red.
Brieﬂy, the yeast culture in the middle of the logarithmic phase was
incubated in PDB medium for 2 h at 37 °C in the presence of 12.5 μM
Hb40-61a and in the absence of peptide (control). Subsequently, the in-
cubated cells were treatedwith amixture of SYTO 9 and PI, as described
previously [41,43]. The cells were analyzed using a Fluorescence
Microscopy Nikon Eclipse, TE300 (Tokyo, Japan). Three independent
experiments were performed. Cells treated with 70% isopropanol were
used as a positive control.2.6. Plasma membrane potential
Log-phased C. albicans ATCC 90028 cells (2 × 106 cells) in Sabouraud
medium were harvested by centrifugation, washed three times,
suspended in a PDB and treated with 12.5 or 25 μM Hb40-61a (½ MIC
or MIC value) for 2 h at 37 °C. Melittin (3.2 μM) was used as positive
control. After incubation, the cells were centrifuged, washed three
times with PDB and treated with 3 μL (1.8 μM) of the membrane-
potential-sensitive ﬂuorescent probe bis-(1,3-dibutylbarbituric acid)
pentamethine oxonol [DiBAC4(5); Molecular Probes, Eugene/OR, USA]
for 5 min at room temperature in the dark. Fluorescence was measured
at the excitation and emission wavelengths of 590 nm and 616 nm, re-
spectively, using a Cytomics FC500 ﬂow cytometry system (Beckman
Coulter Inc., CA, USA).
2.7. Interaction of FAM-Hb40-61a with C. albicans cells
Log-phased C. albicans ATCC 90028 (2 × 106 cells) were washed
three times with PDB and suspended on the same medium. FAM-
Hb40-61a was added to 200 μL of cell suspension at 12.5 or 25 μM (½
MIC or MIC value). After 15 min at 37 °C, the cells were centrifuged
for 5 min at 8000 g, washed three times with PDB and ﬁxed with
0.37% formaldehyde by 20 min. Localization of FAM-Hb40-61a in
C. albicansATCC 90028 cellswasdone on a Carl Zeiss LSM510 laser scan-
ning confocal microscopy (Carl Zeiss MicroImaging GmbH, Göttingen,
Germany) equipped with an argon/krypton laser. At least three indepen-
dent experiments were performed.
2.8. Fluorescence analysis of 1,6-diphenyl-1,3,5-hexatriene (DPH)
C. albicans ATCC 90028 cells (2 × 106) were treated with various
concentrations (6.25, 12.5, 25, 62.5 and 125 μM)ofHb40-61a ormelittin
for 1 h at 37 °C, ﬁxed with 0.37% formaldehyde, collected, washed with
PBS (pH 7.4) and incubated with 3.75 μM of DPH (Molecular Probes,
Eugene/OR, USA) for 45 min at 37 °C and, ﬁnally, washed with PDB.
Fluorescence was measured at 450 nm (excitation at 350 nm) using a
Spectrophotometer Hitachi, F-7000 (Tokyo, Japan) because DPH is a
ﬂuorogenic probe classically used to examine the effects of membrane
active drugs because its optical characteristics strongly dependent on
the environment: interaction with hydrophobic region of the mem-
brane results in a sharp increase in the ﬂuorescence signal at 450 nm
(excitation at 350 nm); exposure to water results in major decrease of
such signal.
2.9. Effect of NaN3 on antifungal activity
C. albicansATCC 90028 cells (2× 106)were pre-incubated for 30min
at 37 °C with a solution 0.05% NaN3, then washed three times with PDB.
FAM-Hb40-61a (25 μM) and NaN3 (0.05%) were added to cell suspen-
sion. After incubation at 37 °C for 15 min, the cells were centrifuged
for 5 min at 8000 g, washed three times with PDB and suspended
in 1 mL of PBS. Internalization of FAM-Hb40-61a was monitored on a
Cytomics FC500 ﬂow cytometry system (Beckman Coulter Inc., CA,
USA).
3. Results
3.1. Peptide synthesis, puriﬁcation and chemical characterization
Independently on the resin used, all steps of peptide assembly at 60 °C
were fast and gave reasonable yields. The desired peptides were the
major components of the crude materials. Puriﬁcation followed
by characterization provided the results shown in Fig. 1 and supplemen-
tary Table 1 (Table S1). Purities were higher than 98%. Peptide contents
were higher than 60%.
Fig. 1. Characterization of the synthetic peptidesHb40-61a (A), D-Hb40-61a (B) and FAM-Hb40-61a (C). RP-HPLC proﬁles before (A1, B1, C1) and after (A2, B2, C2) puriﬁcation. ESI-MS of
the puriﬁed peptides (A3, B3, C3).
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The ability of the puriﬁed peptides to inhibit the growth (MIC)
of C. albicans ATCC 90028, C. krusei ATCC 6258 and C. parapsilosis
ATCC 22019 is shown in Table 1. At pH 5.5 (pH suitable for the yeast)Table 1






MICs are expressed as the intervals of concentrations [a]–[b], where [a] is the highest concentr
that inhibits the visible microbial growth. Melittin was used as control, giving MIC of 25.0 μM
a pH 5.5.
b pH 7.4.Hb40-61a and D-Hb40-61a were equipotent, but FAM-Hb40-61a was
less active. At neutral pH (7.4, chosen due to its physiological impor-
tance) Hb40-61a was signiﬁcantly less active than at pH 5.5.
As to the candidacidal activity, the minimal fungicidal concentra-











ation tested at which the microorganism was growing and [b] is the lowest concentration
against C. albicans ATCC 90028.
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To assess the therapeutical potentials of these peptides Hb40-61a,
D-Hb40-61a and FAM-Hb40-61awere also tested on human erythro-
cytes in two different buffers: PBS and IGP, having the ﬁrst high ionic
strength and the second low ionic strength and osmolarity corrected
by glucose addition. Fig. 2 shows that, as expected in PBS buffer,
all three peptides were not hemolytic, but in IGP buffer, they cause
low hemolysis (Hb40-61a: less than 25%; D-Hb40-61a: less than
25%; FAM-Hb40-61a: less than 27%). TI calculated for the three pep-
tides are: 0.5 for Hb40-61a, 0.5 for D-Hb40-61a and 0.25 for FAM-
Hb40-61a.Fig. 2.Hemolytic activity (%)measured towards human erythrocytes in PBS and IGP buffer
at peptide concentration ranging from 0.19 to 100 μM at 37 °C for 1 h. (A) Hb40-61a;
(B) D-Hb40-61a and (C) FAM-Hb40-61a. The bars represent standard deviation of three
independent experiments.3.4. Membrane damage caused by Hb40-61a
C. albicans treated with 70% isopropanol, used as positive control,
displayed red ﬂuorescence as a result of permeabilization of cellular
plasma membrane. When the green-ﬂuorescent nucleic acid stain
SYTO 9 and the red PI were added to cells treated with Hb40-61a at
12.5 μM (MIC) for 2 h, the observed red ﬂuorescence (Fig. 3) indicated
PI incorporation as consequence of permeabilization of the yeast cells
plasma membrane. On the other hand, when both dyes were added to
C. albicans cells untreated with the peptide, only green ﬂuorescence
was detected conﬁrming plasma membrane integrity. These results
showed that Hb40-61a damages the yeast cell plasma membrane,
allowing PI incorporation.3.5. Membrane potential assay
Membrane depolarization has been implicated in the mode of
action of many AMPs, so C. albicans ATCC 90028 cells were incu-
bated with increasing concentrations of Hb40-61a for 2 h at 30 °C
and subsequently treated with the dye membrane potential sensi-
tive dye DiBAC4(5) for 5 min. Fluorescence increase dependent on
peptide concentration was observed, indicating a pronounced de-
polarization of the yeast cell plasma membrane since this type of
dye only enters depolarized cells where it binds to intracellular
proteins or membranes to exhibit enhanced ﬂuorescence. As ex-
pected, cells treated with Hb40-61a or the positive control
melittin showed more accumulation of DiBAC4(5) than untreated
cells (Fig. 4). As can also be seen, ΔΨ was dissipated by treatment
with the peptides.3.6. Cell exposure to FAM-Hb40-61a
To verify whether the peptide has a speciﬁc target in the cell, the
ﬂuorescent labeled peptide FAM-Hb40-61a was incubated in the ab-
sence and presence of 0.9% NaCl with C. albicans ATCC 90028 for
15min followed by observation of the cells by FACS (Fig. 5) and confocal
laser scanning microscopy (Fig. 5). The ﬁrst one showed that: (i) in the
absence of NaCl about 97% or 75% of cells were marked with peptide at
its MIC (25.0 μM) (Fig. 5B) or ½ MIC (12.5 μM; data not shown),
respectively; (ii) when pre-incubated and incubated with NaN3, 86%
of the cells marked with peptide at its MIC (Fig. 5C); and (iii) at high
salt concentration, only 37% of the cells were marked with the peptide
at its MIC (Fig. 5D).
Confocal microscopy revealed that at½MIC (12.5 μM) the peptide is
deposited around themembrane (Fig. 6A–B), but at theMIC (25.0 μM) it
stains most of the cells and is distributed in the cytoplasm (Fig. 6C–D).
These results indicated that there is a minimal concentration of peptide
required to promote extensive structural perturbation in the mem-
brane, allowing permeabilization.3.7. Fluorescence intensity of the plasma membrane
Since the probe DPH is a hydrophobic molecule that associates with
the hydrocarbon tail region of phospholipids, within natural and
synthetic membranes, without disturbing the structure of the lipid
bilayer, this is helpful for examining dynamics and ﬂuidity of plasma
membranes [51]. When used to conﬁrm if the plasma membrane is
actuallyHb40-61a central target in C. albicans cells, DPH presented ﬂuo-
rescence intensity dependent on peptide concentration (Fig. 7), indica-
tive of relative changes in DPH environment. Because ﬂuorescence
anisotropy was not measured, these results were considered only sug-
gestive of changes in the dynamics of the yeast cell plasma membrane
due to exposure to Hb40-61a.
Fig. 3.Membranepermeability assay of log-phasedC. albicans (2× 106 cells) in the presence ofHb40-61a for 2 h and stainedwith theﬂuorescent dyes SYTO 9 andpropidium iodide at 37 °C
for 1 h. Identical proﬁles were veriﬁed in three independent experiments.
Fig. 4. Flow cytometric histograms representing thenumber of events (cells) observed byﬂuorescence emission at 616nm(FL1) starting from log-phased C. albicans (2 × 106 cells) stained
with DiBAC4(5) not incubated (shaded distribution) or incubated at 37 °C for 2 h (empty distribution)with peptide: 3.2 μMmelittin (A) or 12.5 μMHb40-61a (B) or 25.0 μMHb40-61a (C).
Identical proﬁles were veriﬁed in three independent experiments.
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Fig. 5. Flow cytometry analysis using FAM-Hb40-61a. Log-phased C. albicans (2 × 106 cells) were treated with the labeled peptide at different concentrations at 37 °C for 15 min.
(A) untreated cells, (B) 25.0 μM FAM-Hb40-61a, (C) 25.0 μM FAM-Hb40-61a in the presence of 0.05% NaN3 and (D) 25.0 μM FAM-Hb40-61a in the presence of 0.9% NaCl. Dotplots showed
the ﬂuorescence intensity of C. albicans treated with the labeled peptide. FS Log (y-axis) and FL1 Log (x-axis) are indicators of the size and ﬂuorescence intensity, respectively.
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4.1. Synthesis, anticandidal, candidacidal and hemolytic activities of
Hb40-61a and analogues
In the present study we ﬁrst focused on the possibility of achieving
faster, cleaner and more productive syntheses. Here we show that we
succeeded by using the combination of Fmoc chemistry and protocols
previously optimized in our laboratory for performing each step of the
process at 60 °C [44,45,46,50]: manual peptide assembly on resin was
signiﬁcantly fast and cleaner (no dichloromethane was used), in com-
parison to those previously obtained by Boc chemistry the new crude
peptides (obtained without the use of HF) were less heterogeneous
and the syntheses ﬁnal yields were higher, validating our protocols for
stepwise SPPS at 60 °C of hemocidins derived from bovine α-
hemoglobin, for stepwise SPPS in general and, also, for cost-effective
synthesis of ﬂuorescent labeled peptides.
As to the antifungal and fungicidal activities of the synthetics obtain-
ed, Clinical and Laboratory Standard Institute (CLSI) recommends the
use of dilution methods for cell susceptibility test because they are
more reproducible in comparison to diffusion methods in agar plates
[52]. So, in the present study, liquid growth inhibition assays were per-
formed. Inspired in previous studies focused on cationic AMPs [24,43],
low salt concentration was mostly used to avoid competition between
cations for the interaction with the negatively charged groups of the
cell wall/plasma membrane and, consequently, to allow observing theimpact of L-amino acids replacement by D-amino acids or N-acylation
with FAM on MIC and MFC of Hb40-61a.
The fact that the puriﬁed Hb40-61a and its mirror image, isomer
D-Hb40-61a, presented identical MICs when tested against C. albicans
strains indicated that the natural hemocidin Hb33-61 [24] and its
synthetic analogues Hb33-61a and Hb40-61a [43] work through a
non-chiral or nonstereospeciﬁc mechanism, but is mostly due to direct
peptide–lipid interactions. This lack of stereospeciﬁcity has also been
observed in working mechanisms of the most known AMPs [53],
although there are reports on expression of anticandidal activity by
some AMPs through interaction with proteins on plasma membrane
(for instance, histatin-5 seems to interact with Ssa1/2p heat shock pro-
tein [54]).
The decrease of Hb40-61a antifungal activity owing to its labeling
with 5-(6) carboxyﬂuorescein (FAM) was not wanted. Such negative
effect seems to be associatedwith the high volume andhydrophobic na-
ture of FAM moiety, which certainly affected the peptide amphipathic
nature, overall charge and 3D structure in solution [43]. On the other
hand, the labeling with FAM, one of themost popular green ﬂuorescent
reagents used for labeling AMPs such as penetratin [55] and shepherin I
[50], allowed performing experiments based on confocal laser scanning
microscopy and ﬂow cytometric analysis that provided important infor-
mation to be discussed below.
As expected, at pH 5.5 Hb40-61a has a theoretical net charge of +6
owing to the presence in its structure of three histidine, three lysine
and one glutamic acid residues, but at pH 7.4 this peptide has theoretical
Fig. 6. Confocal analysis using FAM-Hb40-61a. Log-phased C. albicans (2 × 106 cells) treated with the labeled peptide at (A–B) 12.5 μM and (C–D) 25.0 μM at 37 °C for 15 min. Identical
proﬁles were veriﬁed in three independent experiments.
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plementary Fig. 1; Fig. S1) Having found that our synthetic hemocidin
ismore active at pH5.5 (more appropriate for the growth of the Candida
strains used) than at neutral pH, our results highlight the importance of
protonation of such basic amino acid residues for the ﬁrst step of Hb40-
61a's mode of action: electrostatic interaction with the negatively
charged phospholipids present in the plasma membrane. Besides,
these results are in agreement with: (i) the information that the AMPs
activities are dependent on their microenvironments (indeed, various
chemokines, defensins and LL-37 are partially, or completely, antago-
nized by either high salt conditions or the presence of plasma proteins
in vitro [49]; (ii) previous studies of histidine-rich AMPs describing de-
creased activity at pH 7.4 and restored effect at pH 5.5 [49,56].
Since Hb40-61a, its all-D isomer and FAM-Hb40-61a showed poor
and similar hemolytic activity, but the MIC of FAM-Hb40-61a at
pH 5.5 was 4 times higher, their therapeutic indexes (TI) were 0.50,
0.50 and 0.25, respectively. Therefore, Hb40-61a and its all-D ana-
logue seem to behave identically, being the last more resistant
against proteolysis.4.2. Candida plasmamembrane is the ﬁrst and ultimate target of Hb40-61a
Our present results show thatHb40-61awas able to: (i) permeabilize
the yeast plasma membrane since it allowed the incorporation of the
dye PI; (ii) cause pronounced depolarization of the yeast plasma mem-
brane evidenced by the enhancement of its ﬂuorescence coming from
the potential-sensitive dye DiBAC4(5); and (iii) cause the decrease of
ﬂuorescence of suchmembrane stainedwithDPH, suggestive of changes
in this ﬂuorogenic probe's environment and, therefore, structural
perturbation of the membrane [51,57]. Besides, its analogue composed
solely of D-amino acids is as active as Hb40-61a. Moreover, FAM-Hb40-
61a localized at the C. albicans plasma membrane at the ½ MIC, but
stained the whole cell at the MIC.
Because of these results and considering that (i) the experiment
performed with Hb40-61a in the presence of NaN3 revealed that
C. albicans cells was only partially desensitized to this peptide, (ii) sodi-
um azide (NaN3) is an inhibitor of intracellular ATP production during
mitochondria respiration, which further prevents membrane active
transport [58], (iii) ATP depletion has been claimed to induce several
Fig. 7. DPH ﬂuorescence intensity after treatment with Hb40-61a (○) or with melittin
(●; control), the last used as control. The error bars represent the standard deviation for
three independent experiments.
3148 L.A.C. Carvalho et al. / Biochimica et Biophysica Acta 1848 (2015) 3140–3149changes in cellular physiological conditions by regulating the intra-
cellular pH and rigidifying the plasma membrane [59], (iv) Candida is
a facultative microorganism (thus, some ATP could be produced by
fermentation), and (v) our results rejected any possibility of Hb40-61a
internalization into the yeast cells by endocytosis [60], we propose
here that the anticandidal and candidacidal actions of Hb40-61a under
the conditions used in the presentwork are at the level of the yeast plas-
mamembrane: it initially gets associated with its lipid bilayer and, after
reaching a threshold concentration, it permeabilizes or disintegrates the
membrane, altering its potential (and possibly affecting its dynamics);
pores may be formed frommicelle-like units. In other words, the linear
cationic Hb40-61a seems to work as a typical membrane-active linear
amphipathic AMP.
Although our present data are not sufﬁcient for conﬁrming such
proposition, this is compatible to our previous data on the ability of
Hb33-61,Hb33-61a andHb40-61a to assume structured regions, jointed
by a central hinge, that ﬂuctuate independently in the lipid environ-
ment and act in a coordinated fashion to disturb the yeast plasma
membrane [41,43]. This is also in agreement with the working mecha-
nism of other linear amphipathic peptides, such as dermaseptin [61],
aurein 1.2 [62] and antimicrobial peptide LL-37 [63] that act by the
so-called “carpet” mechanism [64]. We are currently attempting to
shed more light on the working mode of Hb40-61a by examining its
association/interaction with phospholipids micelles and bilayers (large
vesicles and giant vesicles).
5. Conclusions
The growing number of infections byC. albicans, the increasingnum-
ber of resistant strains and the elevated toxicity of many antifungals
have stimulated the search for new agents not only able to kill Candida
strains, but alsowith very low host toxicity and/or resistance index. This
study showed that: (i) the Hb40-61a, its all-D analogue and its ﬂuores-
cently labeled analogue can be easily obtained by solid-phase synthesis
using Fmoc-chemistry at 60 °C in all steps, which saves time and avoids
the use of chloride solvents and HF; (ii) this practically not hemolytic
Hb40-61a exhibits relatively elevated anticandidal and candidacidal ac-
tivities via a membrane-active mechanism that involves perme-
abilization, and change of potential probably owing to changes in the
dynamics of the yeast plasma membrane. Hence, this is an artiﬁcial
hemocidin with potential for topic uses in therapeutics. Being formed
by only D-amino acids and presenting exactly the same MIC against
Candidas, its D-Hb40-61a seems to be even more interesting.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2015.09.010.
Conﬂict of interest
We have no conﬂict of interest to declare.
Acknowledgments
This research was supported by Pro-Reitoria USP, FAPESP (2008/
11695-1, 2012/09068-4: ﬁnancing of our peptide chemistry facility)
and CAPES (for M.Sc. fellowship for LACC). We thank E. Nogueira (for
synthesizing the standard Hb40-61a), Dr. Sandro Rogério de Almeida
(for providing C. albicans ATCC 90028, C. parapsilosis ATCC 22019 and
C. krusei ATCC 6258), Dr. Cleber E. Liria (for amino acid analyses),
Adriana Y. Matzukuma/Wilton J. R. Lima (for assistance with ﬂow cy-
tometry) and Alexsander S. Souza (for confocal microscopy imaging
support, Butantan Institutemulti-user equipment, FAPESP 00/11624-5).
References
[1] M.D. Zilberberg, A.F. Shorr, M.H. Kollef, Secular trends in candidiasis related hospi-
talization in the United States, Infect. Control Hosp. Epidemiol. 29 (2008) 978–980.
[2] M.A. Pfaller, D.J. Diekema, Epidemiology of invasive candidiasis a persistent public
health problem, Clin. Microbiol. Rev. 20 (2007) 133–163.
[3] A.L. Colombo, M. Nucci, B.J. Park, S.A. Nouer, B. Arthington-Skaggs, D.A. Matta, D.
Warnock, J. Morgan, Epidemiology of candidemia in Brazil: a nation sentinel surveil-
lance of candidemia in eleven medical centers, J. Clin. Microbiol. 44 (2006)
2816–2823.
[4] A.L. Colombo, M. Janini, R. Salomão, E.A.S. Medeiros, S.B. Wey, A.C.C. Pignatari, Sur-
veillance programs for detection and characterization of emergent pathogens and
antimicrobial resistance, Annals Braz. Acad. Sci 81 (2009) 571–587.
[5] D.R. Andes, N. Safdar, J.W. Baddley, G. Playford, A.C. Reboli, J.H. Rex, J.D. Sobel, P.G.
Pappas, B.J. Kullberg, Impact of treatment strategy on outcomes in patients with
candidemia and other forms of invasive candidiasis: a patient-level quantitative re-
view of randomized trials, Clin. Infect. Dis. 54 (2012) 1110–1122.
[6] G. Samonis, D.P. Kofteridis, E. Saloustros, K.P. Giannopoulou, F. Ntziora, A. Christidou,
S. Maraki, M.E. Falagas, Candida albicans versus non-albicans bloodstream infection
in patients in a tertiary hospital: an analysis of microbiological data, Scand. J. Infect.
Dis. 40 (2008) 414–419.
[7] Z.A. Kanafani, J.R. Perfect, Antimicrobial resistance to antifungal agents: mechanisms
and clinical impact, Clin. Infect. Dis. 46 (2008) 120–128.
[8] A.L. Colombo, T. Guimarães, L.R. Silva, L.P. De Almeida Monfardini, A.K. Cunha, P.
Rady, T. Alves, R. Rosas, Prospective observational study of candidemia in São
Paulo, Brazil: incidence rate, epidemiology and predictors of mortality, Infect. Con-
trol Hosp. Epidemiol. 28 (2007) 570–576.
[9] F. Rossi, The challenges of antimicrobial resistance in Brazil, Clin. Infect. Dis. 52
(2011) 1138–1143.
[10] M. Krogh-Madsen, M.C. Arendrup, L. Heslet, D. Knudsen, Amphotericin B and
caspofungin resistance in Candida glabrata isolates recovered from a critically ill
patient, Clin. Infect. Dis. 42 (2006) 938–944.
[11] C.A. Hitchcock, G.W. Pye, P.F. Troke, E.M. Johnson, D.W. Warnock, Fluconazole resis-
tance in Candida glabrata, Antimicrob. Agents Chemother. 37 (1993) 1962–1965.
[12] R. Franz, S.L. Kelly, D.C. Lamb, D.E. Kelly, M. Ruhnke, J. Morschhauser, Multiple mo-
lecular mechanisms contribute to a stepwise development of ﬂuconazole resistance
in clinical Candida albicans strains, Antimicrob. Agents Chemother. 42 (1998)
3056–3072.
[13] D.S. Perlin, Resistance to echinocandin-class antifungal drugs, Drug Resist. Updat. 10
(2007) 121–130.
[14] R.A. Woods, Nystatin-resistance mutants of yeast: alterations in sterol content, J.
Bacteriol. 108 (1971) 69–73.
[15] E.Y. Chekmenev, B.S. Vollmar, M. Cotton, Can antimicrobial peptides scavenge
around a cell in less than a Second? Biochim. Biophys. Acta 1798 (2010) 228–234.
[16] K. Matsuzaki, Control of cell selectivity of antimicrobial peptides, Biochim. Biophys.
Acta 1788 (2009) 1687–1692.
[17] Y. Lai, R.I. Gallo, AMPedup immunity: how antimicrobial peptides have multiple
roles in immune defense, Trends Immunol. 30 (2009) 131–141.
[18] A.K. Marr,W.J. Gooderham, R.E.W. Hancock, Antibacterial peptides for the therapeu-
tic use: obstacles and realistic outlook, Curr. Opin. Pharmacol. 6 (2006) 468–472.
[19] R.E.W. Hancock, H.G. Sahl, Antimicrobial and host-defense peptides as new anti-
infective therapeutic strategies, Nat. Biotechnol. 24 (2006) 1551–1557.
[20] A. Cederlund, G.H. Gudmundsson, B. Agerberth, Antimicrobial peptides important in
innate immunity, FEBS J. 278 (2011) 3942–3947.
[21] P. Mak, K.Wójcik, J. Silberring, A. Dubin, Antimicrobial peptides derived from heme-
containing proteins: hemocidins, Antonie Van Leeuwenhoek 77 (2000) 197–207.
[22] P. Mak, Hemocidins in a functional and structural context of juman antimicrobial
peptides, Front. Biosci. 13 (2008) 6859–6871.
[23] P. Sheshadri, J. Abraham, Antimicrobial properties of hemoglobin, Immunopharmacol.
Immunotoxicol. 34 (2012) 896–900.
3149L.A.C. Carvalho et al. / Biochimica et Biophysica Acta 1848 (2015) 3140–3149[24] A.C. Fogaça, P.I. da Silva Jr, M.T.M. Miranda, A.G. Bianchi, A. Miranda, P.E. Ribolla, S.
Daffre, Antimicrobial activity of a bovine hemoglobin fragment in the tick Boophilus
microplus, J. Biol. Chem. 274 (1999) 25330–25334.
[25] C.A. Parish, H. Jiang, Y. Tokiwa, N. Berova, K. Nakanishi, D. Mccabe, W. Zuckerman,
M. Xia, J.E. Gabay, Broad-spectrum antimicrobial activity of hemoglobin, Bioorg.
Med. Chem. 9 (2001) 377–382.
[26] R. Froidevaux, F. Krier, N. Nedjar-arroume, D. Vercaigne-Marko, E. Kosciarz, C.
Ruckebusch, P. Dhulster, D. Guillochon, Antibacterial activity of a pepsin-derived
bovine hemoglobin fragment, FEBS Lett. 491 (2001) 159–163.
[27] R. Daoud, V. Dubois, L. Bors-Dodita, N. Nedjar-Arroume, F. Krier, N.E. Chihib, P. Mary,
M. Kouach, G. Briand, D. Guillochon, New antibacterial peptide derived from bovine
hemoglobin, Peptides 26 (2005) 713–719.
[28] N. Nedjar-Arroume, V. Dubois-Delval, K. Miloudi, R. Daoud, F. Krier, M. Kouach, G.
Briand, D. Guillochon, Isolation and characterization of four antibacterial peptides
from bovine hemoglobin, Peptides 27 (2006) 2082–2089.
[29] N. Nedjar-Arroume, V. Dudois-Delval, E.Y. Adje, J. Traisnel, F. Krier, P. Mary, M.
Kouach, G. Briand, D. Guillochon, Bovine hemoglobin: an attractive source of anti-
bacterial peptides, Peptides 29 (2008) 969–977.
[30] L. Catiau, J. Traisnel, N.E. Chihib, G. Le Flem, A. Blanpain, O. Melnyl, D. Guillochon, N.
Nedjar-Arroume, RYH: a minimal peptidic sequence obtained from α-chain hemo-
globin exhibiting an antimicrobial activity, Peptides 32 (2011) 1463–1468.
[31] E.Y. Adje, R. Balti, M. Kouach, P. Dhulster, D. Guillochon, N. Nedjar-Arroume,
Obtaining antimicrobial peptides by controlled peptic hydrolysis of bovine hemo-
globin, Int. J. Biol. Macromol. 49 (2011) 143–153.
[32] C. Liepke, S. Baxmann, C. Heine, N. Breithaupt, L. Standker, W.G. Forssmann, Human
hemoglobin-derived peptides exhibit antimicrobial activity: a class of host defense
peptides, J. Chromatogr. B 791 (2003) 345–356.
[33] Y. Nakajima, K. Ogihara, D. Taylor, M. Yamakawa, Antibacterial hemoglobin frag-
ments from the midgut of the soft tick, Ornithodoros moubata (Acari: Argasidae),
J. Med. Entomol. 40 (2003) 78–81.
[34] S.M.S. Tharp, M.R. Ackermann, J.M. Gallup, K.A. Brogden, An ovine hemoglobin frag-
ment inhibits Porphyromonas gingivalis and Micromonas micros, The IADR/AADR/
CADR 85th General Session and Exhibition. New Orleans, LA., 2007.
[35] P. Mak, K. Wójcik, L. Wicherek, P. Suder, A. Dubin, Antibacterial hemoglobin pep-
tides in human menstrual blood, Peptides 25 (2004) 1839–1847.
[36] A.G. Brown, R.S. Leite, A.J. Engler, D.E. Discher, J.F. Strauss, A hemoglobin fragment
found in cervicovaginal ﬂuid from women in labor potentiates the action of agents
that promote contraction of smooth muscle cells, Peptides 27 (2006) 1794–1800.
[37] L. Deng, X. Pan, Y. Wang, L. Wang, X.E. Zhou, M. Li, Y. Feng, Q. Wu, B. Wang, N.
Huang, Hemoglobin and its derived peptides may play a role in the antibacterial
mechanism of the vagina, Hum. Reprod. 24 (2009) 211–218.
[38] J.Hu,M.Xu, B.Hang, L.Wang,Q.Wang, J. Chen, T. Song, D. Fu, Z.Wang, S.Wang, X. Liu,
Isolation and characterization of an antimicrobial peptide from bovine hemoglobin
α-subunit, World J. Microbiol. Biotechnol. 27 (2011) 767–771.
[39] C.E. Cruz, A.C. Fogaça, E.S. Nakayasu, C.B. Angeli, R. Belmonte, I.C. Almeida, A.
Miranda, M.T.M. Miranda, A.S. Tanaka, G.R. Braz, C.S. Craik, E. Schneider, C.R.
Caffrey, S. Daffre, Characterization of proteinases from the midgut of Rhipicephalus
(Boophilus) microplus involved in the generation of antimicrobial peptides, Parasit.
Vectors 3 (2010) 63–78.
[40] L.A.C. Carvalho, M.T. Machini, Hemocidins derived from hemoglobin: structures,
properties and perspectives, Quim. Nova 36 (2013) 1021–1029.
[41] M.L. Sforça, A. Machado, R.C. Figueredo, S. Oyama, F.D. Silva, A. Miranda, S. Daffre,
M.T.M. Miranda, A. Spisni, T.A. Pertinhez, The micelle-bound structure of an antimi-
crobial peptide derived from the alpha-chain of bovine hemoglobin isolated from
the tick Boophilus microplus, Biochemistry 44 (2005) 6440–6451.
[42] H.S. Won, S.J. Jung, H.E. Kim, M.D. Seo, B. Lee, Systematic peptide engineering and
structural characterization to search for the shortest antimicrobial peptide analogue
of gaegurin 5, J. Biolumin. Chemilumin. 279 (2004) 14784–14791.
[43] A. Machado, M.L. Sforça, A. Miranda, S. Daffre, T.A. Pertinhez, A. Spisni, M.T.M.
Miranda, Truncation of amidated fragment 33–61 of bovine alpha-hemoglobin:
effects on the structure and anticandidal activity, Biopolymers 88 (2007) 413–426.[44] L.M. Varanda,M.T.Miranda, Solid-phase peptide synthesis at elevated temperatures:
a search for and optimized synthesis condition of unsulfated cholecystokinin-12, J.
Pept. Res. 50 (1997) 102–108.
[45] M.P. Souza, M.F.M. Tavares, M.T.M. Miranda, Racemization in stepwise solid-phase
peptide synthesis at elevated temperatures, Tetrahedron 60 (2004) 4671–4681.
[46] C. Loffredo, N.A. Assunção, M.T.M. Miranda, Further studies on peptide synthesis on
high temperature. Peptides for Youth, Adv. Exp. Med. Biol. 611 (2009) 165–166.
[47] J. Fernández-Carneado, E. Giralt, An efﬁcient method for the solid-phase synthesis of
ﬂuorescently labelled peptides, Tetrahedron Lett. 45 (2004) 6079–6081.
[48] S. Kiyota, L. Franzoni, G. Nicastro, A. Benedetti, S. Oyama, W. Viviani, A.G. Gambarini,
A. Spisni, M.T.M. Miranda, Introduction of a chemical constraint in a short peptide
derived from human acidic ﬁbroblast growth factor elicits mitogenic structural
determinants, J. Med. Chem. 46 (2003) 2325–2333.
[49] L. Kacprzy, V. Rydengard, M. Morgelin, M. Davoudi, M. Pasupuleti, M. Malmsten, A.
Schmidtchen, Antimicrobial activity of histidine-rich peptides is dependent on acid-
ic conditions, Biochim. Biophys. Acta 1768 (2007) 2667–2680.
[50] C. Remuzgo, T.S. Oewel, S. Daffre, T.R.S. Lopes, F.H. Dyszy, S. Schreier, G.M. Machado-
Santelli, M.T. Machini, Chemical synthesis, structure–activity relationship and prop-
erties of shepherin I: a fungicidal peptide enriched in glycine–glycine–histidine
motifs, Amino Acids 46 (2014) 2573–2586.
[51] Y. Kushnareva, Membrane Fluidity Measurements Using UV Fluorescence Polariza-
tion and the POLARstar Omega. BMG Labtec Application Note 205, Rev. 12/2009.
[52] Clinical and Laboratory Standards Institute, Reference method for broth dilution an-
tifungal susceptibility testing of yeasts; Approved standard, CLSI document M27-A3,
3rd editionCLSI, Wayne, PA, 2008.
[53] Z. Oren, Y. Shai, Mode of action of linear amphipathic α-helical antimicrobial pep-
tide, Biopolymers 47 (1998) 451–463.
[54] X.S. Li, M.S. Reddy, D. Baev, M. Edgerton, Candida albicans Ssa1/2p is the cell enve-
lope binding protein for human salivary histatin 5, J. Biol. Chem. 278 (2003)
28553–28561.
[55] A. Hansen, I. Schafer, D. Knappe, P. Seibel, R. Hoffmann, Intracellular toxicity of
proline-rich antimicrobial peptides shuttled into mammalian cells by the cell-
penetrating peptide penetratin, Antimicrob. Agents Chemother. 56 (2012)
5194–5201.
[56] I.H. Lee, Y. Cho, R.I. Lehrer, Effects of pH and salinity on the antimicrobial properties
of clavanins, Infect. Immun. 65 (1997) 2898–2903.
[57] C. Park, D.G. Lee, Fungicidal effect of antimicrobial peptide arenicin-1, Biochim.
Biophys. Acta 1788 (2009) 1790–1796.
[58] D.F. Wilson, B. Chance, Azide inhibition of mitochondrial eletron transport. I. The
aerobic steady state of succinate oxidation, Biochim. Biophys. Acta 131 (1967)
421–430.
[59] E.C. Veerman, M. Valentin-Benz, K. Nazmi, A.L. Ruissen, E. Walgreen-Weterings, J.
van Marle, A.B. Doust, W. van't Hof, J.G. Bolscher, A.V. Amerongen, Energy depletion
protects Candida albicans against antimicrobial peptides by rigidifying its cell mem-
brane, J. Biol. Chem. 282 (2007) 18831–18841.
[60] Y. Sai, M. Kajita, I. Tamai, J. Wakama, T. Wakamiya, A. Tsuji, Adsorptive-mediated en-
docytosis of a basic peptide in enterocyte-like caco-2 cells, Am. J. Phys. 275 (1998)
G514–G520.
[61] Y. Pouny, D. Rapaport, A. Mor, P. Nicolas, Y. Shai, Interaction of antimicrobial
dermaseptin and its ﬂuorescently labeled analogs with phospholipid membranes,
Biochemistry 31 (1992) 12416–12423.
[62] D.I. Fernandez, A.P. Le Brun, T.C. Whitwell, M.A. Sani, M. James, F. Separovic, The
antimicrobial peptide aurein 1.2 disrupts model membranes via the carpet mecha-
nism, Phys. Chem. Chem. Phys. 14 (2012) 15739–15751.
[63] F. Neville, M. Cahuzac, O. Konovalov, Y. Ishitsuka, K.Y.C. Lee, I. Kuzmenko, G.M. Kale,
D. Gidalevitz, Lipid headgroup discrimination by antimicrobial peptide LL-37:
insight into mechanism of action, Biophys. J. 90 (2006) 1275–1287.
[64] R. Pálffy, R. Gardlík, M. Behuliak, L. Kadasi, J. Turna, P. Celec, On the physiology and
pathophysiology of antimicrobial peptide, Mol. Med. 15 (2009) 51–59.
